Rucaparib Camsylate
Overview
Rucaparib Camsylate is a small molecule inhibitor targeting the enzyme Poly (ADP-ribose) polymerase (PARP), used in the treatment of ovarian cancer. It works by interfering with DNA repair mechanisms, thus promoting cell death in cancer cells.
API suppliers (3)
Suppliers of Rucaparib Camsylate evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
Country recorded for 2 of 3 suppliers.
2 of 3 hold a GMP certificate on record in the EU or UK registers
- Formosa Laboratories, Inc.Taiwan1 active DMF GMP on record
- MSN Laboratories Private LimitedIndia1 active DMF GMP on record
- BIOPHORE INDIA PHARMACEUTICALS PVT LTD1 active DMF
Patent & exclusivity (US)
Per the FDA Orange Book (3 approved US products), the latest listed US patent on Rucaparib Camsylate expires 17 Aug 2035 and exclusivity 17 Dec 2028. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Rucaparib Camsylate? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.